investigated the integration of NBTXR3-enhanced localized radiation with the concurrent inhibition of three distinct checkpoint receptors—PD1, LAG3, and TIGIT—and evaluated the effectiveness of this treatment was evaluated in a murine model of anti-PD1-resistant lung cancer. The findings decisively supported the efficacy and validity of integrating nanoparticle-enhanced radiotherapy with concurrent inhibition of multiple immune checkpoint receptors. Here, LAG3 is linked to lung cancer.